Abstract
Effect of Chlormadinon acetate (CMA) on human benign prostatic hypertrophy was studied by a double-blind trial using Paraprost (PPC) as control.
Measurements made before and after treatment demonstrated improvement in most of the assessment items both in CMA and PPC groups. CMA group showed significant improvement as compared with PPC group in assessments of dysuria, loss of force of urinary stream and rising of bladder base (significant level: α=0.05) and retardatory urination (α=0.10). Global judgement that CMA group signi ficantly exceeded PPC group at α=0.10 was given.
Diarrhea was observed in each one case of both groups. Decrease in potents was found in three cases of CMA group. No side effects on liver and renal function were noticed in both groups.
